Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo

2205.207 - 2230.647 Dr. Bogdana Schmidt

And that's why we do all of it, which makes perfect sense. But now that we have really great EV PEMBRO data for metastatic disease, and I know you don't have a crystal ball to tell me for sure how using checkpoint up front will impact that data. But what do you think? Are you worried that it'll make that data look worse? Or do you hope that it'll make it look better because of a priming effect?